MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

doi:10.1158/1078-0432.CCR-14-3091

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Dec 2015

García-García Celina, Rivas Martín A, Ibrahim Yasir H, Calvo María Teresa, Gris-Oliver Albert, Rodríguez Olga, Grueso Judit, Antón Pilar, Guzmán Marta, Aura Claudia, Nuciforo Paolo, Jessen Katti, Argilés Guillem, Dienstmann Rodrigo, Bertotti Andrea, Trusolino Livio, Matito Judit, Vivancos Ana, Chicote Irene, Palmer Héctor G, Tabernero Josep, Scaltriti Maurizio, Baselga José, Serra Violeta

Abstract excerpt

PURPOSE: PI3K pathway activation occurs in concomitance with RAS/BRAF mutations in colorectal cancer, limiting the sensitivity to targeted therapies. Several clinical studies are being conducted to test the tolerability and clinical activity of dual MEK and PI3K pathway blockade in solid tumors. EXPERIMENTAL DESIGN: In the present study, we explored the efficacy of dual pathway blockade in colorectal cancer...

Topics

Animals
Antineoplastic Agents
Apoptosis
Cell Cycle
Cell Line, Tumor
Cell Proliferation
Colorectal Neoplasms
Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Disease Models, Animal

Drug Synergism

Extracellular Signal-Regulated MAP Kinases

Female

Humans

Mechanistic Target of Rapamycin Complex 1

Mechanistic Target of Rapamycin Complex 2

Mice

Multiprotein Complexes

Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 26272063
DOI: 10.1158/1078-0432.CCR-14-3091
PMCID: PMC5087596

Genes

BRAF
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-26272063-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.PMID 26272063Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinomaSemantic proximity Read ↗

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.Semantic proximity Read ↗

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.Semantic proximity Read ↗

Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6.Semantic proximity Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.Semantic proximity Read ↗

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancerSemantic proximity Read ↗

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.Semantic proximity Read ↗

Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.